GSK’s (GSK) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their underweight rating on shares of GSK (LON:GSK) in a research note released on Tuesday morning, MarketBeat.com reports.

Separately, Berenberg Bank lowered their price target on shares of GSK from GBX 1,820 ($22.39) to GBX 1,600 ($19.69) and set a “buy” rating on the stock in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.22).

GSK Price Performance

LON GSK opened at GBX 1,349.50 ($16.61) on Tuesday. The firm’s 50 day moving average is GBX 1,352.59 and its 200-day moving average is GBX 1,480.33. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The company has a market capitalization of £55.06 billion, a PE ratio of 1,194.25, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 12-month low of GBX 1,282.50 ($15.78) and a 12-month high of GBX 1,823.50 ($22.44).

GSK Dividend Announcement

The company also recently declared a dividend, which was paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th were given a dividend of GBX 15 ($0.18) per share. This represents a yield of 1.03%. The ex-dividend date was Thursday, November 14th. GSK’s dividend payout ratio (DPR) is currently 5,309.73%.

Insider Activity

In other GSK news, insider Jonathan Symonds acquired 1,500 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was bought at an average cost of GBX 1,315 ($16.18) per share, with a total value of £19,725 ($24,270.95). Insiders bought a total of 8,658 shares of company stock valued at $11,950,792 in the last quarter. Company insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.